A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Sponsor:

COG

Sponsor Study ID:

ANBL2131

CTO #:

104176

NCT Number:

NCT06172296

Phase:

III

Protocol Type:

Treatment

Age Group:

Children

Disease Sites:

Kidney

Study Objectives:

To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)